We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Show more
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.13 | 7.92682926829 | 1.64 | 1.75 | 1.5 | 15570 | 1.61374618 | CS |
4 | -0.03 | -1.66666666667 | 1.8 | 1.97 | 1.49 | 27534 | 1.67028628 | CS |
12 | 0.09 | 5.35714285714 | 1.68 | 2.3399 | 1.49 | 32331 | 1.92638266 | CS |
26 | 0.24 | 15.6862745098 | 1.53 | 2.3399 | 1.3 | 69184 | 1.88214619 | CS |
52 | -8.13 | -82.1212121212 | 9.9 | 26.4 | 1.08 | 721597 | 11.60601441 | CS |
156 | -463.31 | -99.6194203148 | 465.08 | 637.56 | 1.08 | 2866558 | 141.38375565 | CS |
260 | -1913.99 | -99.9076084687 | 1915.76 | 4989.6 | 1.08 | 2539707 | 329.64095521 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions